Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 in B-cell non-Hodgkin lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies. Despite the success, treatment failure due to CD19 antigen loss, mutation, or down-regulation remains the main obstacle to cure...
| Hlavní autoři: | , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
Frontiers Media S.A.
2024-04-01
|
| Edice: | Frontiers in Oncology |
| Témata: | |
| On-line přístup: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1396395/full |